The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.

How is TNKase administered?

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.

How Was TNKase approved?

The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.

How Common Are These Strokes?

In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.

TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."

What Are The Symptoms Of Ischemic Strokes?

Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.

Other symptoms include:

• Loss of coordination or clumsiness
• Blurry vision or double vision
• Dizziness or vertigo
• Nausea and vomiting
• Neck stiffness
• Mood swings or sudden personality changes
• Confusion or agitation
• Seizures
• Memory loss (amnesia)
• Headaches which are sudden and severe
• Passing out or fainting
• Coma

Are There Any Warning Signs?

While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.

In a landmark judgement, the Supreme Court today allowed passive euthanasia for a 32-year-old man, living in a vegetative state for the last 13 years.

A bench comprising Justice JB Pardiwala and Justice KV Viswanathan allowed the withdrawal of life support for Harish Rana, a resident of Ghaziabad, who has been in a coma and kept alive on tubes for breathing and nutrition after sustaining severe head injuries following a fall from a building in 2013 in Chandigarh.

It is the first known case of a court-ordered passive euthanasia in India, since it was legalised in 2018 and modified in 2023, recognizing the fundamental right to die with dignity.

"Harish Rana, presently aged 32 years, was once a young, bright boy. He met with a tragic life-altering accident after a fall from the fourth floor of his paying guest accommodation. His brain injury left him in a condition of Persistent Vegetative State (PSV) with 100 percent quadraplegia... Medical reports show that his medical condition has not improved in the past 13 years," LiveLaw quoted the bench as saying.

The Court noted that the continuation of his treatment -- Clinically Administered Nutrition (CAN) via surgically installed PEG tubes -- can just prolong his biological existence but will not lead to any therapeutic improvement.

What Is The Case Of Harish Rana?

Harish was a BTech student in Chandigarh who suffered severe traumatic brain injury after falling from the fourth floor of his paying guest accommodation in August 2013.

Since then, he has remained bedridden and dependent on others for all activities of daily life.

Harish's father, the petitioner, first approached the Delhi High Court in 2024, seeking permission for passive euthanasia, but was rejected as the patient was not terminally ill.

The same year, the petitioner knocked on the doors of the Supreme Court, which, though it refused to entertain the plea, directed the Uttar Pradesh government to bear the treatment expenses.

In 2025, the petitioner filed a miscellaneous application in the Supreme Court, noting that Harish's condition had no scope for improvement.

The Court then directed the constitution of a Primary Medical Board led by the District Hospital in Noida to examine his health, as well as a Secondary Medical Board constituted by the All India Institute of Medical Sciences (AIIMS).

After perusing the report, Justice Pardiwala remarked that it's a "sad report" and the man can't continue to live like this. Before passing the final order, the Court met the parents, LiveLaw reported.

The Court has asked AIIMS to provide palliative care, so that the withdrawal of CAN can be given effect to.

To maintain the dignity of death, the apex Court said that the life support must be withdrawn with a tailored plan.

1st Passive Euthanasia: What's New From The 2018 Judgment

In 2018, a five-judge Constitution Bench had recognized and given sanction for passive euthanasia, and living will/advance directives.

Later in 2023, the SC modified the guidelines, noting that withdrawal of life support is permissible only after the approval of the Primary and Secondary Medical Boards.

With the Harish Rana judgment, the apex Court today clarified how passive euthanasia should be applied in cases where a patient’s life is being supported by feeding tubes.

The top Court waived off the reconsideration period of 30 days and noted that the medical treatment, including the CAN administered to the patient, can be withdrawn or withheld.

What is Passive Euthanasia

Passive Euthanasia allows a terminally ill or irreversibly comatose patient to die naturally. It involves deliberately withholding or withdrawing life-sustaining treatments (like ventilators, feeding tubes, or medication). It has been legal since 2018, but under strict guidelines.

In Active Euthanasia, patients are administered a lethal injection to cause death. It is illegal in India and considered an offence.

The Aruna Shanbaug case in 2011 opened the door for passive euthanasia in India for the first time.

The top Court rejected euthanasia in the case of Shanbaug, a nurse at Mumbai's KEM hospital who was in a vegetative state for 42 years after an assault in 1973, as the hospital staff who cared for her for decades did not support stopping treatment.

Shanbaug continued to be under care and passed away naturally in 2015

However, in her case, the court made the judgment allowing for passive euthanasia in certain rare situations under strict conditions.

About 6 million people in India's capital city are living with several vision problems, such as poor distance vision or near vision, according to a recent study by doctors at All India Institute of Medical Sciences (AIIMS), New Delhi.

The study, Dr. Rajendra Prasad Centre for Ophthalmic Sciences at AIIMS, and submitted to the World Health Organization (WHO), also flagged major gaps in eye care services in Delhi, the Times of India reported.

An estimated one-third of the population in the national capital was identified with refractive errors or presbyopia -- conditions that can usually be corrected with a pair of glasses. Globally, 826 million people suffer from presbyopia.

About 70 percent of older adults in the capital city were identified with the problem.

Alarmingly, about 13.1 percent school-going children had refractive errors, Dr. Praveen Vashist, professor and head of community ophthalmology at AIIMS, was quoted as saying.

Gaps In Eye Care

The study showed a lack of access to vision correction. While just 60 percent of people needing distance vision correction could access care, those with near vision correction could access care in over 47 percent of cases.

Further, the doctors found:

• women had the lowest access to spectacles compared to men
• lack of trained eye care workers,
• the affordability of spectacles,
• limited outreach to vulnerable groups -- elderly patients, rural women, and economically weaker populations.

But Dr. Vashisth noted that Delhi currently has only 1,085 ophthalmologists and approximately 489 optometrists.

Further, only 50 community-level vision centers, out of the has 249 eye care institutions in the city were found to be functioning. Moreover, only about 25 percent of children were receiving free spectacles through public health initiatives.

Global Eye Burden

According to the World Health Organization (WHO), at least 2.2 billion people worldwide have near or distance vision impairment. Of these, at least 1 billion cases could be prevented with increased access to eyeglasses and cataract surgeries

The WHO identifies refractive errors and cataracts as the leading causes of vision impairment and blindness.

Vision loss can affect people of all ages; however, most people with vision impairment and blindness are over the age of 50.

Here's how to maintain a healthy vision:

• Eat fruits and veggies, especially leafy greens like spinach, kale, and fish like salmon and tuna, to protect your sight.
• Be physically active, as being overweight or obese can increase risk for diabetes and other conditions that can lead to vision problems.
• If your vision gets blurry, use glasses to help you see better.
• Always wash your hands before putting them close to your eyes, especially if you’re putting in or taking out contact lenses.
• Use protective eyewear while playing a favorite sport or mowing the lawn
• Wear your shades to prevent the sun’s rays from hurting your eyes.
• Give your eyes a break with the 20-20-20 rule: Every 20 minutes, look about 20 feet away for 20 seconds.
• Quit smoking as it can put you at risk of serious eye issues, leading to blindness.

Ibuflam tablets by pharmaceutical manufacturer Zentiva under the brand name Lichtenstein has been recalled. The 600mg tablets of ibuprofen products were recalled due to contamination. As per several media reports, a piece of metal was found in the tablet which triggered the recall. As per the manufacturer, the affected tablet are the 50-tablet packs with the batch number 5R02514.

Zentiva stated that the recall is explicitly directed at wholesalers and pharmacies, as the company confirmed upon request and the recall is not directed on patients. This measure was taken as a precautionary measure and in consultation with the relevant regulatory authorities.

As of now, patients have the option to return packages from the affected batch and receiving a replacement.

Also Read: Leucovorin Approved By FDA But For A Rare Genetic Disease, Not For Autism

How Can You Return And Receive A New Ibuprofen Prescription?

As per Zentiva, the standard procedure of returning packages from the affected batch and receiving a replacement could be availed. For instance, if the package is almost empty, the standard procedure does not need to be followed, as this could potentially be considered a new prescription. However, patients will have the option of returning packages with the batch number.

A Zentiva spokesperson explained, "The possibility of obtaining a replacement through the supplying pharmacy in case of suspected quality defects always exists. Any connection to the recall lies solely in the fact that the suspicion regarding this batch can generally be considered justified."

This is not a case of re-dispensing under the replacement procedure. It is important to note that when a replacement pack is dispensed in response to a quality complaint, the affected medicinal product is not being placed on the market again, but rather a previously prescribed and supposedly defective medicinal product is being replaced.

Read: THIS Alternative Could Help Prevent Gut Damage Caused By Painkillers

What Is Ibuflam Or Ibuprofen?

Ibuprofen is a nonsteroidal anti-inflammatory drug or NSAID that is used to relieve pain, fever, and inflammation. Ibuflam is a brand name which is a combination medication containing ibuprofen and paracetamol or acetaminophen, which is also designed for enhanced pain relief.

As per the World Health Organization (WHO), ibuprofen is on the list of essential medication. The medicine is used by mouth as a syrup or tablet, and could also be applied directly to the skin as a mousse, gel, or spray.

The uses include:

• fever
• inflammation
• headache
• menstrual pain
• common cold
• toothache
• back pain
• arthritis
• sprains

The medicine could have some side effects, which could include pain, diarrhea or constipation, nausea and vomiting, dyspepsia, bloating, dizziness, headache, nervousness, skin rash, tinnitus, edema or fluid retention.

Who Should Not Use Ibuprofen?

Anyone with:

• repeated stomach problems like heartburn
• stomach ulcers
• bleeding problems
• high blood pressure
• heart disease
• kidney disease
• age over 60 years

OR

Anyone who:

• has taken a diuretic
• is using other NSAIDs or pain relief medication
• is using anticoagulants
• is receiving treatment for any serious condition
• has chickenpox or shingles
• has Crohn's disease or ulcerative colitis
• has liver problems